Roche launches new lung, bladder cancer drug in India
Roche says Tecentriq has been approved in India for two types of cancers—non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer
New Delhi: Global pharma major Roche on Wednesday said it has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer.
Tecentriq has shown to extend survival and improve the quality of life in the approved indications, Roche said in a statement. The product has been approved in India “for two types of cancers: non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer”, it added.
The drug will now be available to patients in India on the prescription of oncologists, Roche said. Commenting on the development, Roche Products India Pvt. Ltd managing director Lara Bezerra said: “Bringing Tecentriq to India reflects Roche’s commitment to bring global innovations to the country.”
The company believes that Tecentriq will play an important role in the treatment of people with advanced bladder cancer and metastatic non-small cell lung cancer in India, she added.
“Roche has helped transform the treatment of cancer globally, and will continue to set newer standards of care for cancer patients in India,” Bezerra said. Tecentriq is a monoclonal antibody used for treatment of metastatic non-small cell lung cancer and metastatic urothelial carcinoma. It is a cancer immunotherapy drug that is designed to work with body’s natural defence system.
Editor's Picks »
- Karnataka govt formation: Kingmaker H.D. Kumaraswamy becomes the king
- CLAT 2018: Supreme Court to hear pleas challenging law entrance exam held on 13 May
- Grasim Industries Q4 net profit at Rs 853.62 crore
- Govt waives Rs1,077 crore penal interest on loans to Paradip Port
- Hyatt brings Hyatt Centric brand to India
- Same-store sales growth trips at Future Retail
- Cipla Q4 FY18 results no reason to reverse stock underperformance
- Dr Reddy’s Q4: It’s a wait and watch, share price spike notwithstanding
- What SBI Q4 results say about the Indian economy and the bank
- Patanjali’s slowing growth does not mean that Colgate’s is accelerating